US MoCRA for SME cosmetic brands
MoCRA expanded FDA’s cosmetics authority: facility and product listing, safety substantiation, serious adverse event reporting, and a still-moving rulemaking calendar.
MoCRA
2026 Q2 desk: SCCS season, China methods, MoCRA status board
Five things that actually moved a calendar in Q2: SCCS triage, China method packs, mercury date approaching, FDA Voices, leftover MoCRA rules.
MoCRA 2026 status board: live duties vs leftover rules
Listing and serious AE reporting are live. GMP, allergen labeling and the asbestos method are still a calendar. Brief the board with two columns.
FDA Voices (2026): MoCRA implementation progress — treat as a status board
FDA’s May 2026 Voices post walks listing, PFAS report, and leftover rulemakings. Useful as a checklist against the MoCRA statute page.
FDA PFAS-in-cosmetics report (29 Dec 2025): data gap, not a federal ban
FDA’s MoCRA-mandated PFAS report found evidence too thin for safety determinations on most intentionally added PFAS. State bans can still apply.
US professional-use cosmetics: MoCRA labeling expectations still apply
“Salon only” is not a MoCRA off-ramp. Adverse-event contact and other required statements still need a home on the pack or the mandated alternative.
FDA withdrew the proposed asbestos test method for talc cosmetics (28 Nov 2025)
The December 2024 proposed rule on standardized asbestos testing in talc cosmetics was withdrawn. MoCRA still directs FDA to work this problem — a withdrawal is not a permission slip.
MoCRA leftover rules (GMP, fragrance allergens, asbestos method): still a calendar, not a code
Statutory target dates for some MoCRA rules have slipped. Track FDA’s MoCRA page. Do not implement a draft you cannot cite.